Epetraborole is under clinical development by AN2 Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Epetraborole’s likelihood of approval (LoA) and phase transition for Mycobacterium avium Infections took place on 10 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Epetraborole Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Epetraborole overview

Epetraborole is under development for the treatment of mycobacterium avium complex, or MAC, the most common type of NTM, mycobacterium abscessus and melioidosis. The drug candidate is administered as intravenous infusion and through oral route. It is a systemic antibiotic. It acts by targeting the bacterial enzyme leucyl tRNA synthetase. Leucyl tRNA synthetase is an alpha monomer. It is developed based on boron chemistry technology platform.

It was also under development for gram-negative bacterial infections including Enterobacteriaceae infections, Escherichia coli infections, Klebsiella pneumoniae infections and complicated urinary tract infections including acute pyelonephritis and intra-abdominal infections.

AN2 Therapeutics overview

AN2 Therapeutics is a biopharmaceutical company. The company is focused on the research, development, and commercialization of medicines targeting infectious diseases. An2 Therapeutics is headquartered in the US.

Quick View Epetraborole LOA Data

Report Segments
  • Innovator
Drug Name
  • Epetraborole
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: AN2 Therapeutics
  • Originator: Anacor Pharmaceuticals
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.